163 related articles for article (PubMed ID: 38143257)
1. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.
Yang Z; Lu S; Shi M; Yuan H; Wang Z; Ni Z; He C; Zheng Y; Zhu Z; Liu W; Yao X; Zhang J; Li C; Yan M; Yan C; Zhu Z
Gastric Cancer; 2024 Mar; 27(2):387-399. PubMed ID: 38143257
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
3. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases.
Saito S; Yamaguchi H; Ohzawa H; Miyato H; Kanamaru R; Kurashina K; Hosoya Y; Lefor AK; Sata N; Kitayama J
Ann Surg Oncol; 2021 Jul; 28(7):3863-3870. PubMed ID: 33270170
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Lum JHY; Nga ME; Goh GH; Seet JE; Chee CE; Tan HL; Ho J; Ngoi NYL; Lee MXW; Muthu V; Chan GHJ; Pang ASL; Ang YLE; Choo JRE; Lim JSJ; Teh JL; Lwin A; Soon Y; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2022 Dec; 29(13):8597-8605. PubMed ID: 36070113
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Shinkai M; Imano M; Hiraki Y; Momose K; Kato H; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Yasuda T
Langenbecks Arch Surg; 2022 May; 407(3):975-983. PubMed ID: 34988644
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
10. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
11. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
13. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
Zhang X; Huang H; Yang D; Wang P; Huang X; Hu Z; Zhang Y; Yan R; Zhu Z; Cai Q
Technol Cancer Res Treat; 2021; 20():15330338211036310. PubMed ID: 34328799
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
[TBL] [Abstract][Full Text] [Related]
16. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
Ishigami H; Fujiwara Y; Fukushima R; Nashimoto A; Yabusaki H; Imano M; Imamoto H; Kodera Y; Uenosono Y; Amagai K; Kadowaki S; Miwa H; Yamaguchi H; Yamaguchi T; Miyaji T; Kitayama J
J Clin Oncol; 2018 Jul; 36(19):1922-1929. PubMed ID: 29746229
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Emoto S; Kitayama J; Ishigami H; Yamaguchi H; Watanabe T
Ann Surg Oncol; 2015 Mar; 22(3):780-6. PubMed ID: 25216603
[TBL] [Abstract][Full Text] [Related]
18. [Multidisciplinary treatment for gastric cancer with peritoneal metastasis].
Ishigami H; Kitayama J; Yamaguchi H; Emoto S; Watanabe T
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2460-3. PubMed ID: 23235165
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
20. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Chan DY; Syn NL; Yap R; Phua JN; Soh TI; Chee CE; Nga ME; Shabbir A; So JB; Yong WP
J Gastrointest Surg; 2017 Mar; 21(3):425-433. PubMed ID: 27981493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
